Validating New NIH Clinical Tools in Parkinson's Disease with/without Depressio

描述（由申请人提供）：本申请涉及广泛的挑战领域（05）比较有效性研究和特定挑战主题，05- ns -103：验证NIH在神经疾病人群中的新临床工具。帕金森病（PD）和抑郁症的临床影响是公认的，具有相当大的临床意义，但人们对它们在生活质量和认知结果方面的独特作用和复杂相互作用知之甚少。因此，测量PD患者的生活质量和神经认知功能，特别是在存在共病抑郁症的情况下，可能具有预后意义。标准评估工具已被用于评估帕金森病和抑郁症的生活质量和神经认知影响，但其使用受到心理测量学特性差和更重要的是给药时间长的限制。为了克服这些限制，NIH开发了两个重要的工具，健康相关生活质量（neuroqol）测量和NIH神经和行为功能工具箱评估（NIH工具箱）。然而，neuroqol和NIH工具箱在帕金森病患者中尚未标准化。本研究验证新的NIH帕金森病伴/无抑郁症临床工具，将在160名帕金森病患者的代表性和描述良好的队列中使用neuroqol和NIH工具箱（目的1），并将识别可归因于帕金森病或抑郁症状的影响（目的2）。这个拟议的项目将推进NINDS的使命，即开发新的标准化测试，作为NIH神经科学蓝图的一部分，特别是帕金森病和共病抑郁症患者的生活质量和神经认知测量。此外，该项目将解决美国复苏和再投资法案的目标：1)基础设施投资——通过开展多学科研究，为当前和未来的努力创建一个协同的心理测试开发平台；2)就业保留和创造——通过雇用现有教师、早期职业调查者和雇用新的研究人员和博士后学者。这个项目的有效设计是在两年的时间框架内完成，包括统计分析。

DESCRIPTION (provided by applicant): This application addresses broad Challenge Area (05) Comparative Effectiveness Research and specific Challenge Topic, 05-NS-103: Validating NIH's New Clinical Tools in Populations with Neurological Disorders. The clinical impact of Parkinson's Disease (PD) and depression are well recognized and of considerable clinical significance, but less understood is their unique role and complex interaction in terms of quality of life and cognitive outcomes. As such, measurement of quality of life and neurocognitive function in patients with PD, particularly in the presence of comorbid depression, may have prognostic significance. Standard assessment tools have been used to evaluate quality of life and neurocognitive effects of PD and depression, but their use has been limited by poor psychometric properties and more importantly, lengthy administration time. To overcome these limitations, NIH developed two important tools, the Health-Related Quality of Life (Neuro-QOL) measure, and the NIH Toolbox Assessment of Neurological and Behavioral Function (NIH Toolbox). However, the Neuro-QOL and the NIH Toolbox have not been standardized in patients with Parkinson's disease. This research study Validating New NIH Clinical Tools in Parkinson's Disease with/without Depression will utilize the Neuro-QOL and the NIH Toolbox in a representative and well described cohort of 160 patients with Parkinson's disease (aim 1) and will discern the effects attributable to Parkinson's or depressive symptomatology (aim 2). This proposed project will advance NINDS' mission of developing new standardized tests as part of the NIH Blueprint for neuroscience, particularly quality of life and neurocognitive measures, in patients with Parkinson's disease and comorbid depression. Further, this project will address the American Recovery and Reinvestment Act goals of 1) infrastructure investment - through conducting multidisciplinary research to create a synergistic psychometric test development platform for present and future endeavors, and 2) job preservation and creation - by employing current faculty, early career investigators and hiring new research personnel and postdoctoral scholars. This project is efficiently designed to be completed, inclusive of statistical analyses, within a two-year time frame. PUBLIC HEALTH RELEVANCE: This project is significant as it addresses scientific knowledge gaps in sophisticated quality of life and neurocognitive assessment tools, specifically the Neuro-QOL and the NIH Toolbox neurocognitive battery, through the use of a well-controlled psychometric research study. The Neuro-QOL and NIH Toolbox will be administered in a cohort of patients with Parkinson's disease with and without depression to optimize their use in the research and clinical arenas. Further, this project will discern the quality of life and neurocognitive effects attributable to Parkinson's or depressive symptomatology.